Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months ...

Abbott has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volttm PFA System ...

Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt PFA SystemThe 12-month results of the ...

Abbott (NYSE: ABT) today announced new study data demonstrating the safety and efficacy of its Volt pulsed field ablation ...

Pulmonary embolism (PE) is a significant cause of morbidity and mortality, particularly in patients classified as acute, ...

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

Jurny, the leading agentic AI platform transforming hospitality operations at scale, today announced a major expansion of its executive leadership and advisory board. The move adds world-class ...

One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal AfibDual-energy ...

Atrial fibrillation is the most common chronic arrhythmia. It is characterized by erratic atrial electrical activity with atrial rates of 400 to 600 beats per minute. The P wave is absent on the ...

Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation ... have already suffered an acute non-cardioembolic ischaemic ...

Atrial fibrillation (AF) is the most common cardiac ... rivaroxaban uptake in patients with AF include unfamiliarity with management of interruption and bleeding, and cost of the drug.